Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of Temferon in glioblastoma multiforme
2024-516211-25-00Phase 2Authorised
- Sponsor
- Genenta Science
- Start
- Aug 2024
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Temferon in glioblastoma (GBM), sponsored by Genenta Science. Primary endpoint: Mutagenic potential of Temferon. Planned start Aug 2024; status: authorised.
02
Drugs
Temferon
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-516211-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516211-25-00.